Clinical Trial Update: A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating Xaluritamig in combination with Abiraterone vs investigator's choice in chemotherapy-naïve metastatic castration-resistant pros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Xaluritamig (Xaluritamig)

Snippet

Sponsor: Amgen | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: RECRUITING